AXSOME THERAPEUTICS INC. - COMMON STOCK

Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference

05 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

27 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

20 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20

23 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones

04 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting

11 дек 2023 07:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today

07 дек 2023 07:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7

22 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference

21 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

06 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023

02 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Present at Upcoming Investor Conferences

31 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference

24 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors

11 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6

10 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week

02 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day

21 сен 2023 07:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023

07 сен 2023 07:03:16 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

07 авг 2023 07:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7

12 июл 2023 07:00:00 Источник Nasdaq GlobeNewswire